Form 4: Bolt Biotherapeutics Exec Reprices Stock Options
Insider Transaction Report
Bolt Biotherapeutics Senior VP, Finance and PAO, Sarah Nemec, exchanged multiple employee stock options for new options with significantly lower exercise prices on December 12, 2025.
Summary
- Sarah Nemec, Senior VP, Finance and PAO of Bolt Biotherapeutics, Inc. (BOLT), reported a series of employee stock option transactions on December 12, 2025.
- Nemec disposed of 30,995 employee stock options with exercise prices ranging from $7.02 to $400.
- Concurrently, Nemec acquired 30,995 new employee stock options, all with a significantly lower exercise price of $5.44.
- These transactions represent a repricing of previously granted options, where older, higher-priced options were cancelled in exchange for new options at a lower strike price.
- The new options have various vesting schedules, with some vesting 1/36th per month following specific start dates (e.g., January 1, 2023; January 1, 2024; July 15, 2024; January 1, 2025) and others being fully vested and exercisable immediately.
Sentiment
Score: 3
Explanation: The repricing of executive stock options is generally a negative signal for investors, indicating past stock underperformance and potential concerns about corporate governance and shareholder dilution. While it may aid executive retention, the market typically views such actions unfavorably.
Positives
- The reporting person, Sarah Nemec, benefits from significantly lower exercise prices on 30,995 employee stock options, enhancing the potential value of her equity compensation.
- The repricing may serve as a retention tool for key management personnel, particularly if the company's stock price has underperformed, by re-aligning incentives.
Negatives
- The repricing of options suggests that the company's stock price has fallen significantly, rendering the original options 'underwater' and indicating past underperformance.
- Option repricing is generally viewed negatively by shareholders as it effectively re-grants compensation at a lower bar, potentially diluting existing shareholders if more shares are issued upon exercise at a lower price.
- The original exercise prices, some as high as $400, indicate a substantial decline in the perceived value of the company's stock since those options were initially granted.
Risks
- Shareholder dilution risk if the stock price recovers and these lower-priced options are exercised, increasing the number of outstanding shares.
- Negative perception regarding executive compensation practices, as repricing can be seen as insulating management from poor stock performance.
- Implied risk of continued stock price volatility or underperformance, given the need to reprice options to maintain executive incentives.
Future Outlook
The filing does not provide forward-looking statements regarding the company's financial performance or strategic direction, beyond the vesting schedules for the newly granted employee stock options, which are contingent on continuous service to the Issuer.
Management Comments
- The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price.
- The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price.
- The reporting person agreed to cancellation of an option granted on December 22, 2021, in exchange for a new option having a lower exercise price.
- The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price.
- The reporting person agreed to cancellation of an option granted on January 19, 2023, in exchange for a new option having a lower exercise price.
- The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price.
- The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price.
- The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.
Industry Context
Option repricing often occurs in industries like biotechnology, where stock prices can be highly volatile and subject to significant fluctuations based on clinical trial results, regulatory approvals, and market sentiment. When a company's stock price declines substantially, options granted at higher prices become 'underwater,' losing their incentive value. Repricing is a mechanism used to restore this incentive and retain key talent, though it can be controversial.
Comparison to Industry Standards
- Option repricing, while not uncommon in certain market conditions, is generally viewed unfavorably by corporate governance advocates and institutional investors compared to best practices in executive compensation.
- Companies like Apple or Microsoft, known for strong governance, typically avoid repricing options, preferring to issue new grants at current market prices or tie compensation to performance metrics.
- In the biotech sector, companies facing significant stock price declines, such as those experiencing clinical setbacks, might consider repricing to retain critical scientific or executive talent, similar to historical instances seen with smaller, development-stage biotechs struggling with market valuation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Compensation Adjustment | The company's compensation committee (or board) approved the cancellation of existing, higher-priced employee stock options for Senior VP, Finance and PAO Sarah Nemec, and the re-granting of new options at a significantly lower exercise price of $5.44. This decision impacts the incentive structure for a key executive. | 2025-12-12 | This action aims to re-incentivize the executive following a period of stock price decline, but it may raise questions among shareholders regarding the alignment of executive compensation with long-term shareholder value and the company's overall governance practices related to equity awards. |
Stakeholder Impact
- Shareholders: Potential negative impact due to perceived dilution from lower-priced options and concerns over executive compensation practices following stock underperformance.
- Employees (specifically Sarah Nemec): Positive impact as her equity compensation is re-incentivized, potentially improving retention and motivation.
- Board of Directors/Compensation Committee: The decision reflects their strategy to retain key talent, but may face scrutiny from investors regarding governance implications.
Next Steps
- The newly acquired options for Sarah Nemec will continue to vest according to their respective schedules, contingent on her continuous service to Bolt Biotherapeutics.
Key Dates
| Date | Description |
|---|---|
| 2020-09-03 | Grant date of an option that was subsequently cancelled and repriced. |
| 2021-02-04 | Grant date of an option that was subsequently cancelled and repriced. |
| 2021-12-22 | Grant date of an option that was subsequently cancelled and repriced. |
| 2022-02-18 | Grant date of an option that was subsequently cancelled and repriced. |
| 2023-01-01 | Vesting commencement date for a portion of the repriced options (1/36th monthly). |
| 2023-01-19 | Grant date of an option that was subsequently cancelled and repriced. |
| 2024-01-01 | Vesting commencement date for a portion of the repriced options (1/36th monthly). |
| 2024-03-04 | Grant date of an option that was subsequently cancelled and repriced. |
| 2024-07-15 | Vesting commencement date for a portion of the repriced options (1/36th monthly). |
| 2024-07-23 | Grant date of an option that was subsequently cancelled and repriced. |
| 2025-01-01 | Vesting commencement date for a portion of the repriced options (1/36th monthly). |
| 2025-05-01 | Grant date of an option that was subsequently cancelled and repriced. |
| 2025-12-12 | Date of the option repricing transactions. |
| 2025-12-16 | Date the Form 4 was filed. |
| 2030-09-02 | Expiration date for a set of repriced options. |
| 2031-02-03 | Expiration date for a set of repriced options. |
| 2031-12-21 | Expiration date for a set of repriced options. |
| 2032-02-17 | Expiration date for a set of repriced options. |
| 2033-01-18 | Expiration date for a set of repriced options. |
| 2034-03-03 | Expiration date for a set of repriced options. |
| 2034-07-22 | Expiration date for a set of repriced options. |
| 2035-04-30 | Expiration date for a set of repriced options. |
Recommendation
holdWhile option repricing is generally a negative signal, indicating past stock underperformance and potential governance concerns, this Form 4 only details transactions for one executive. A 'hold' recommendation is appropriate as it signals caution due to the repricing event, but without broader company financial or strategic updates, a stronger 'sell' might be premature. Investors should monitor future company performance and broader compensation policies.
Keywords
Bolt Biotherapeutics, BOLT, SEC Form 4, stock options, option repricing, executive compensation, insider transaction, beneficial ownership, equity compensation, financial reporting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.